21-23 August 2017

Boston, MA, USA

Speakers

Expand/Collapse

Cynthia Lander
Chief Executive Officer
Moerae Matrix, Inc.

Cynthia Lander, PhD, is a successful entrepreneur who has created, invested in and advised a variety of innovative start-up companies in the biotechnology, diagnostics and medical device industries.  Cynthia has over 25 years of research and leadership experience and is currently Chairman and Chief Executive Officer of the inflammation and fibrosis therapeutics company, Moerae Matrix, which she co-founded.  She is also fulfilling the CEO role for Moerae spin-off VasoPrep Surgical, a medical device entity focused on improving outcomes in vascular graft surgeries. Prior to creating her own companies and advising others, Cynthia was a partner in the venture incubator Nascent Enterprises, with 26 companies created to date and 12 exit transactions.  She also ran her own consulting practice, Cynapse Consulting, advising major pharmaceutical and biotechnology company clients.   She has been Senior Vice President at Publicis Groupe, responsible for business development and brand strategy for biopharmaceutical clients. Cynthia received her PhD in Neuroscience from Yale University (Neurogen Fellow), where she made several discoveries that were subsequently outlicensed for use in research and drug development.  She conducted post-doctoral research at Rockefeller University as a Revson Fellow. Life sciences represents Cynthia’s second career.  Previously, she was a classical musician trained at The Juilliard School (keyboard performance), and she still takes every opportunity possible to play the compositions of Debussy, Liszt, Franck and Bach.  In addition to her PhD, Cynthia has a BS in Psychology from New York University.

Day One

Tuesday 22 August, 2017

12.10 | Enhancing Anti-Inflammatory Effects as Measured by Serum IL-6; Lessons learned from the development of a novel, rationally-designed cell-penetrating peptide inhibitor of MK2

12.30 | Session Q&A Panel

Day Two

Wednesday 23 August 2017

09.30 | Roundtable Sessions Followed by Moderator Feedback & Audience Debate

A. Bruce Montgomery
Chief Executive Officer
Genoa Pharmaceuticals

Bruce Montgomery is CEO of Genoa Pharmaceuticals and has more than 25 years of life science operations and financing experience. Prior to Genoa, Dr. Montgomery served as Chief Executive Officer of Cardeas, Senior Vice President of Gilead Sciences, and founder and Chief Executive Officer of Corus Pharma (acquired by Gilead in 2006). Dr. Montgomery also served as Executive Vice President of R&D at PathoGenesis Corporation until its acquisition by Chiron in 2000. Dr. Montgomery has raised over 250 million dollars in venture and public financings, and serves on the board of Alder, Cytodyne, and Xencor Pharmaceuticals. In 1998, Dr. Montgomery was recognized by the FDA Commissioner with a special citation for leadership in the development and approval of TOBI. For this work, Dr. Montgomery also received the Inventor of the Year award from the University of Washington and received a scientific achievement award from the Cystic Fibrosis Foundation for his work on medications which collectively have extended the average life span of cystic fibrosis patients by over a decade. Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. In 2012, Dr. Montgomery was honored as one of the top 150 living graduates of the University of Washington College of Arts and Sciences in conjunction with the 150th anniversary of the university. Dr. Montgomery is a board certified internist and pulmonologist.

Clifford D. Wright
Ph.D, Principal
RespirPharm Solutions LLC

Dr. Clifford Wright received academic training in microbiology with an immunology emphasis. He received his B.S. and M.S. degrees from Brigham Young University and his Ph.D. degree from the University of Minnesota. Dr. Wright’s professional career has focused on the discovery and development of therapeutic agents for a variety of pulmonary indications, working on both small molecule and biological therapeutics. His primary research interests are the biochemistry, cell biology, and molecular biology of such disorders. Dr. Wright’s career stops include: Parke-Davis Pharmaceutical Research division of the Warner-Lambert Co. (Ann Arbor, Michigan and Freiburg, Germany); Amgen Inc. (Thousand Oaks, California, Boulder. Colorado, and Seattle, Washington); and Gilead Sciences, Inc. (Seattle, Washington). Most recently, he founded RespirPharm Solutions LLC to provide consulting services to industry and academia regard drug discovery and development.

Cory M. Hogaboam
Professor of Medicine
Cedars-Sinai Medical Center

The laboratory of Cory Hogaboam, PhD, is focused on elucidating innate and adaptive immune mechanisms that drive chronic lung diseases such as asthma, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), and idiopathic interstitial pneumonias (IIPs; like idiopathic pulmonary fibrosis). Lab members are particularly interested in understanding the manner in which lung structural cells are impacted by these disease processes.

Day Two

Wednesday 23 August 2017

09.10 | Session Q&A Panel

08.30 | Target Validation in Humanized Mouse Models of Pulmonary Fibrosis

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

Day One

Tuesday 22 August, 2017

11.30 | Mining the Microbiome to Discover & Characterize Novel Pathways of Disease Onset and Progression

12.30 | Session Q&A Panel

Gerald Horan
Principal Investigator
Celgene Corporation

Gerald has 18 years of experience in biotech, working in both drug discovery as well as translational medicine. He has worked in biomarker development and mechanistic studies for multiple drugs curently developed in IBD, as well as for drugs targeting fibrotic diseases. He represents translational development on cross-functional study teams supporting IBD clinical trials and manages collaborative interactions with academic investigators.

Day Two

Wednesday 23 August 2017

16.30 | Session Q&A Panel

16.20 | Development of JNK Inhibitors for the Treatment of IPF

Glenn Rosen
Head, Discovery Fibrosis Biology
Bristol-Myers Squibb

Dr. Rosen received his MD degree from the University of Pennsylvania, followed by specialized basic research training in pulmonary medicine at UCSF and Washington University of St. Louis, before starting his academic career at Stanford. At Stanford, Dr. Rosen led an active basic and translational research program concentrated in the study of apoptosis and fibrosis, with a focus on the characterization of activated signaling pathways leading to fibrosis and resistance to apoptosis. He followed up with the characterization of anti-fibrotic compounds. Dr. Rosen also started and directed the Clinical Interstitial Lung Disease Program at Stanford. He was lead investigator on numerous clinical trials and participated in steering committees and advisory boards for the development of novel therapeutics in fibrotic diseases. Dr. Rosen’s desire to focus on drug development in fibrosis led him to join Bristol-Myers Squibb BMS in September, 2014. Given his translational expertise, Dr. Rosen played an integral role in the clinical and research programs in fibrosis drug development at BMS in his role as Therapeutic Area Head in Fibrosis. He recently was appointed Head, Discovery Fibrosis Biology at BMS.

Day One

Tuesday 22 August, 2017

12.30 | Session Q&A Panel

11.10 | Collagen Biomarkers in IPF: Novel Insights into Disease Pathogenesis and Progression

Gregory Cosgrove
CMO
Pulmonary Fibrosis Foundation

Day One

Tuesday 22 August, 2017

10.00 | Session Q&A Panel

09.00 | Overview & Review of Idiopathic Pulmonary Fibrosis Drug Development

Day Two

Wednesday 23 August 2017

09.30 | Roundtable Sessions Followed by Moderator Feedback & Audience Debate

James A. Cardelli
Chief Executive Officer
Segue Therapeutics LLC

Dr. Cardelli received a B.S. in Biochemistry and Molecular Biology in 1973 from the University of Illinois in Champaign-Urbana and a Ph.D. in Molecular Biology and Molecular Oncology from the University of Wisconsin in Madison, Wisconsin in 1977. Following Post-Doctoral training in Oncology and Infectious Disease, Dr. Cardelli joined the faculty in the Department of Microbiology and Immunology at LSUHSC-S. He was promoted to an Associate Professor in 1989 and a Full Professor in 1993. His laboratory focused on mechanisms of survival of intracellular pathogenic bacteria from 1985 – 2005. From 2005-2015 Dr. Cardelli’s laboratory studied the molecular mechanisms regulating tumor cell invasion. Dr. Cardelli trained over 25 graduate and post-doctoral students while on the faculty at the University of Wisconsin and LSUHSC-S and he is an author on over 130 papers. Dr. Cardelli has garnered highly relevant experience in a managerial role. In addition to his directing a laboratory that average nine personnel for over 25 years, he was Director of Basic and Translational Research from 1997 to 2012 (a division that consisted of five different research programs), he promoted a yearly cancer research symposium and e organized a biweekly seminar series. In addition, Dr. Cardelli was Co-Director (from 2005 – 2011) and became Director (2011-2014) of a drug discovery and development program named Innovative North Louisiana Experimental Therapeutics. This program successfully aided a number of investigators in drug discovery at schools throughout Louisiana generating over $7M in grant funding with a budget that totalled $1M from 2010-2014. INLET received four sponsored research agreements, and filed over 10 patent applications. INLET also developed productive interactions with other Universities including: University of Louisiana at Monroe, Louisiana Tech, Pennington Biomedical Research Center, LSUHSC-S-New Orleans, LSUHSC-S New Orleans, and LSU-S. Dr. Cardelli was named an Adjunct Professor at Louisiana Tech and ULM. Dr. Cardelli retired at the end of 2015 to start the asset and IP holding company Segue Therapeutics followed by Segue Science Management (Technology Transfer and commercialization), Segue Science Labs (Drug Discovery and Contract Research), and SegueTx-Pancreatic Cancer (Development of Repurposed drugs for Fibrosis.  

Day One

Tuesday 22 August, 2017

17.00 | Session Q&A Panel

16.00 | High Content Imaging Screens to Identify Drugs that Impact Fibrosis

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Day One

Tuesday 22 August, 2017

15.00 | Session Q&A Panel

13.30 | Utilizing Patient Derived Systems to Advance Drug Discovery in IPF

Joan Nichols
Professor - Internal Medicine, Microbiology & Immunology
UTMB

Joan E. Nichols is an immunologist with expertise in tissue engineering. Her research focuses on emerging infectious diseases, development of vaccines and the human immune response to pathogens. She has expertise in microbial pathogens, tissue injury and disease pathogenesis, stem cell characterization/differentiation, wound healing, lung defence and respiratory pathogens.

Day One

Tuesday 22 August, 2017

15.00 | Session Q&A Panel

14.40 | Lung-On-A-Chip: A New Frontier for In Vitro Modelling of Lung Fibrosis Within Pharmaceutical Research

Joe Arron
Senior Director, Immunology Research
Genentech

Day One

Tuesday 22 August, 2017

10.00 | Session Q&A Panel

09.20 | Biomarkers and Mechanistic Insights from Clinical Studies of Pirfenidone

Jonathan Goldin
Professor of Radiology, Medicine and Bio-Physics Executive Vice Chairman, Department of Radiological Sciences
UCLA

Dr Jonathan Goldin is currently Professor of radiology and medicine at DGSOM UCLA. He trained in pulmonology at UCT, Radiology at St Bartholomew Hospital London & his thoracic fellowship at UCLA. Dr Goldin is executive vice chair of department and director of centre for computer vision & imaging biomarkers. He has over 160 peer reviewed publications to date.

Day Two

Wednesday 23 August 2017

12.30 | Session Q&A Panel

11.30 | Quantitative Imaging Techniques Aiding Subclinical Diagnoses and Offering Translational Lessons for In Vivo Models

Joseph Jacob
Research Collaborator
Mayo Clinic Rochester

Joseph Jacob graduated as a doctor from Imperial College, London. After 2 years working for Medicines sans frontiers in Africa and India he trained as a radiologist at Kings College Hospital, London and Auckland City Hospital, New Zealand. He underwent sub-specialist training in chest radiology and completed an MD(Research) at Imperial College under Professor David Hansell at the Royal Brompton Hospital. His area of special interest is computer-based analysis of CT imaging in interstitial lung disease, specifically IPF. He is currently undertaking a year of research with the Mayo Clinic Rochester, Minnesota, USA.

Day Two

Wednesday 23 August 2017

12.30 | Session Q&A Panel

11.50 | Predicting Outcomes in IPF Using Computer-Based CT Analysis

Kenneth Lipson
Senior Director - Drug Discovery
FibroGen

Kenneth E. Lipson, Ph.D. is currently a Senior Director, Drug Research at FibroGen, Inc., where his primary responsibility is leadership of research efforts related to the CTGF scientific platform.  Dr. Lipson also shares the responsibility of leadership of the FibroGen Research Department. Dr. Lipson has more than 25 years of experience in biotechnology and multinational pharmaceutical companies, including 3M Pharmaceuticals (defunct), Pharmacia (acquired by Pfizer), SUGEN (acquired by Pharmacia and Upjohn) and CIBA-Geigy (now Novartis),  He has served in a variety of scientific and business leadership positions, and worked in multiple therapeutic areas, including oncology, fibrosis, cardiovascular, inflammation, metabolic and infectious diseases, which are all represented in his 80 publications in peer-reviewed journals, 9 patent applications and 12 review articles and book chapters. Dr. Lipson’s drug discovery contributions include 1) creation of the first non-radioactive tyrosine kinase assay suitable for high throughput screening, 2) recommending the selectivity profile for SUGEN’s third generation angiogenesis inhibitor that led to discovery of sunitinib and toceranib and 3) establishment of the cMet kinase inhibitor project that subsequently led to discovery of crizotinib at Pfizer.  In recognition of his scientific contributions in establishment of the cMet kinase inhibitor project, Dr. Lipson was awarded the title of Pharmacia Fellow, of which there were only 165 among the 45,000 employees of Pharmacia. Prior to his industrial experience, Dr. Lipson served on the faculty of the department of Pathology at Temple University Medical School.  Dr. Lipson earned two simultaneous BS degrees in Biology and Chemistry from the University of Toledo, and a Ph.D. in Chemistry from Case Western Reserve University.  His postdoctoral studies at Sloan-Kettering Institute and Temple University Medical School provided additional training in biochemistry, pharmacology, cell biology and molecular biology.

Day Two

Wednesday 23 August 2017

09.10 | Session Q&A Panel

08.50 | From Translation to Clinical Outcomes: Effects of CTGF Blockade in a Mouse Radiation-Induced Lung Fibrosis Model

Gene Colice,
Medical Director & Global Clinical Lead for Tralokinumab
AstraZeneca

Dr Colice has a background in internal medicine with subspecialization in pulmonary and critical care medicine.  He has been with Astrazeneca for three years acting as the global clinical lead for the tralokinumab program.  This program is currently overseeing multiple phase 3 studies in asthma but previously has performed phase 2 studies in ulcerative colitis, atopic dermatitis and idiopathic pulmonary fibrosis.  Prior to joining Astrazeneca Dr Colice was a Professor of Medicine at The George Washington School of Medicine and Director of the Pulmonary/Critical Care/Respiratory Services section at Washington Hospital Center, both in Washington, DC.

Day Two

Wednesday 23 August 2017

16.30 | Session Q&A Panel

16.00 | Tralokinumab in IPF:  Results of a phase 2 trial

Masha Poyurovsky
Vice President, Head of Molecular Signaling
Kadmon

Dr. Poyurovsky serves as Vice President, Molecular Signaling at Kadmon. Dr. Poyurovsky’s focus is small molecule discovery, mechanism of action studies and nonclinical development. Dr. Poyurovsky also works closely with Kadmon’s Business Development team as a scientific liaison. Prior to joining Kadmon in 2011, Dr. Poyurovsky spent more than ten years studying cellular and molecular mechanisms of cancer in an academic setting. Dr. Poyurovsky received her B.S. in Biology from the University of Pittsburgh and her Ph.D. in Biochemistry from Columbia University. Dr. Poyurovsky continued her postgraduate work at Columbia, first as a postdoctoral fellow and then independently, as a staff scientist.

Day One

Tuesday 22 August, 2017

17.00 | Session Q&A Panel

16.20 | Looking Beyond TFG-Beta to ROCK Inhibition as a Key Therapeutic Target in Fibrosis

Phillip Monk
CSO
Synairgen

Day One

Tuesday 22 August, 2017

15.00 | Session Q&A Panel

14.20 | Establishment of an In Vitro Fibroblastic Focus Model Using IPF Patient Cells for Use in Drug Development

Richard Marshall
Vice President - Fibrosis & Lung Injury Discovery Performance Unit
GlaxoSmithKline

Rick Jack
President & Chief Scientific Officer
Promedior Inc.

Rick has been at Promedior since 2014, first as CSO and since 2015 as President and COO as well. He was previously VP R&D at Mitsubishi-Tanabe Pharma USA and prior to that cofounded Triad Therapeutics.  His expertise is in innate immunity and inflammatory diseases developed both as faculty member in the Department of Rheumatology/Immunology at Brigham and Women’s Hospital /Harvard Medical School and in his career in industry.  He received his Ph.D. in immunology at the University of Connecticut Health Center and was a research fellow in immunoparasitology at the International Laboratory for Research on Animal Diseases in Nairobi, Kenya.

Day Two

Wednesday 23 August 2017

15.00 | Session Q&A Panel

14.20 | Pentraxin-2 Therapeutics; Targeting Monocyte & Macrophage Differentiation

Sam Cobb
Chief Executive Officer
AdAlta

Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. As the founding CEO of AdAlta, Sam has raised over $20m in capital from angel investors, venture capital and more recently Sam was involved in taking AdAlta public on the ASX, raising $10m in an oversubscribed IPO.  Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd. Prior to technology commercialisation, Sam worked at the lab bench at Agen Biomedical as a research scientist, developing a diagnostic test for point of care application, Simplify D-dimer, and was involved in taking this product from research through development and to production. Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.

Day Two

Wednesday 23 August 2017

15.00 | Session Q&A Panel

14.00 | i-Bodies: A Novel Therapeutic Approach For IPF

Seth Porter
Vice President, Fibrosis Therapeutics
Fibrogen

I have been at FibroGen Inc, a San Francisco biotechnology company for over 11 years where I am currently Vice President, Fibrosis Therapeutics and project leader for the development of pamrevlumab, a monoclonal antibody against  connective tissue growth factor.  Pamrevlumab is targeted for fibrotic disease and desmoplastic cancer and is currently in Phase 2 clinical trials for IPF, Duchenne Muscular Dystrophy and pancreatic cancer. I received my PhD in biochemistry at Dartmouth College and was a postdoctoral fellow in neurobiology at Washington University Medical School. Since completing my postdoc I have held positions of increasing responsibility in research and development in several biotechnology/pharmaceutical companies

Day One

Tuesday 22 August, 2017

17.00 | Session Q&A Panel

16.40 | Mechanistic Relationships Between Fibrosis and Cancer: Translational Lessons from Preclinical and Clinical Studies of Fibrosis and Cancer

Craig S. Conoscenti
Medical Expert, Interstitial Lung Disease Clinical Development and Medical Affairs, Respiratory
Boehringer Ingelheim Pharmaceuticals, Inc.

Dr Conoscenti has been at Boehringer Ingelheim since 2002.  Prior to joining Boehringer Ingelheim, he was a clinical faculty member and senior consultant in respiratory diseases, concentrating on interstitial lung disease, and senior researcher for 18yrs.  His role at Boehringer Ingelheim is as Medical Expert in Interstitial Lung Disease

Day One

Tuesday 22 August, 2017

09.40 | The Translational Benefits of the Nintedanib MOA

10.00 | Session Q&A Panel

Deborah A. Quinn
Chief Medical Officer
Bellerophon Therapeutics

Deborah A. Quinn, M.D is the Chief Medical Officer of Bellerophon Therapeutics.  She served as Vice President and Medical Lead for the INOpulse programs since January 2015 prior to being appointed Chief Medical Officer in September 2015. Prior to joining Bellerophon, Dr. Quinn held several positions at Novartis Pharmaceuticals AG from December 2006 to January 2015, most recently as medical director for both pulmonary arterial hypertension and heart failure programs. Previously, Dr. Quinn worked at the Massachusetts General Hospital from 1998 to 2011 where she was an Instructor in Medicine from 1998 to 2006 and a Clinical Assistant Professor in Medicine at Harvard Medical School from 2006 to 2011. Dr. Quinn received her postdoctoral training in Medicine and Pulmonary and Critical Care Fellowship at Massachusetts General Hospital. She received an M.D. from the University of Massachusetts Medical School.

Day Two

Wednesday 23 August 2017

14.40 | Role of inhaled Nitric Oxide in the Treatment of Pulmonary Fibrosis

16.30 | Session Q&A Panel

Jan De Backer
CEO
FLUIDDA INC

Jan De Backer is the founder of FLUIDDA INC. He has obtained a PhD in aerospace engineering at Delft University and an MBA at Columbia University/London School of Economics

Day Two

Wednesday 23 August 2017

12.10 | Functional Respiratory Imaging in Idiopathic Pulmonary Fibrosis

12.30 | Session Q&A Panel

Gini Deshpande
CEO
NuMedii

Gini Deshpande, PhD, is the founder and CEO of NuMedii, a next-generation drug discovery company that uses advanced data sciences and artificial intelligence technology to rapidly discover new therapeutics.  As CEO, she structured the critical partnerships with large pharma companies, including Allergan, Astellas, and Aptalis, and raised the initial rounds of financing.  Prior to NuMedii, she helped companies identify optimal markets and whole product solutions for their ground breaking technologies, including Affymetrix (acquired by Thermo Fisher) and iPierian (acquired by Bristol-Myers Squibb).  Prior to that, Gini led innovation at Children's Hospital Boston, the world’s leading pediatric hospital, focused on the creation of new devices for the tiniest of patients. Gini has helped commercialize early stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million. Gini received her Masters in Science from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.

Day Two

Wednesday 23 August 2017

09.30 | Roundtable Sessions Followed by Moderator Feedback & Audience Debate